- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15:48 | Meihua GAAP EPS of $0.40, revenue of $96.91M | 1 | Seeking Alpha | ||
| 12:37 | Meihua International Medical Technologies Co., Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 12:33 | Meihua International Medical Technologies Co., Ltd. - 20-F, Annual and transition report of foreign private issuers | 1 | SEC Filings | ||
| MEIHUA INTERNATIONAL MEDICAL TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 12:30 | Meihua International Medical Technologies Co., Ltd. Full Year Income Retreats | 168 | AFX News | BEIJING (dpa-AFX) - Meihua International Medical Technologies Co., Ltd. (MHUA) released a profit for full year that decreased from the same period last yearThe company's bottom line came in... ► Artikel lesen | |
| 12:05 | Meihua International Medical Technologies Co., Ltd. Reports 2024 Financial Year Results | 45 | PR Newswire | YANGZHOU, China, April 25, 2025 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (Nasdaq: MHUA), a reputable manufacturer... ► Artikel lesen | |
| 03.01. | Meihua International Medical Technologies Co., Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 05.12.24 | Meihua International Medical Technologies Co., Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 07.11.24 | Meihua International bereitet Jahreshauptversammlung vor | 1 | Investing.com Deutsch | ||
| 07.11.24 | Meihua International Prepares for Annual Meeting | 1 | Investing.com | ||
| 06.11.24 | Meihua International Medical Technologies Co., Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 20.09.24 | Meihua International Medical Technologies Co., Ltd.: Meihua International Medical Technologies Co., Limited Reports Unaudited 2024 First Half Financial Results | 226 | PR Newswire | YANGZHOU, China, Sept. 20, 2024 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (Nasdaq: MHUA), a reputable manufacturer and provider of Class I, II... ► Artikel lesen | |
| 31.07.24 | Pre-market Movers: NuZee, Imunon, Meihua International Medical Technologies, Powell Industries, MacroGenics | 818 | AFX News | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.40 A.M. ET).In the Green NuZee, Inc. (NUZE) is up over 51% at $5.60.
Meihua... ► Artikel lesen |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SERNOVA BIOTHERAPEUTICS | 0,126 | -4,55 % | Sernova Aktie: Positives Umsatzwachstum gemeldet! | Das Biotechnologieunternehmen erweitert sein Führungsteam, sichert Finanzierungen und erhält FDA-Freigabe für klinische Studien zur Behandlung von Hypothyreose. Sernova Biotherapeutics, ehemals Sernova... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 0,642 | -0,47 % | Atossa Therapeutics, Inc.: Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio | SEATTLE, April 22, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast... ► Artikel lesen | |
| PING AN HEALTHCARE | 0,804 | 0,00 % | Ping An Healthcare and Technology Company Limited: Ping An Health Reports 25.8% Year-on-Year Revenue Growth in Q1 2025, with Profitability Accelerating | Revenue and Profit Surge, Driven by "AI + Health Care" Value Empowerment
SHANGHAI and HONG KONG, April 24, 2025 /PRNewswire/ -- Ping An Healthcare and Technology... ► Artikel lesen | |
| MOUNTAIN VALLEY MD | 0,013 | 0,00 % | Mountain Valley MD Holdings Inc: Mountain Valley hopes for continued growth in 2025 | ||
| CO-DIAGNOSTICS | 0,320 | +1,91 % | Co-Diagnostics, Inc. Reports Full Year 2024 Financial Results | SALT LAKE CITY, March 27, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the... ► Artikel lesen | |
| CYTOSORBENTS | 1,060 | +4,54 % | CytoSorbents Gains $1.7M Via NJEDA Tax Credit Sale To Fund Strategic Growth | ||
| VERU | 0,468 | -3,70 % | Veru Aktie: Bedeutet das eine Neuausrichtung? | Die Veru-Aktie verliert weiter an Wert, doch Analysten bleiben optimistisch aufgrund vielversprechender Medikamentenentwicklungen. Wird der Tiefpunkt bald erreicht? Die Veru-Aktie setzt ihre Abwärtsspirale... ► Artikel lesen | |
| TEMPEST THERAPEUTICS | 7,050 | -100,00 % | Tempest Therapeutics: Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP | BRISBANE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics... ► Artikel lesen | |
| VOLITIONRX | 0,482 | 0,00 % | VOLITIONRX LTD - 8-K, Current Report | ||
| EKSO BIONICS | 0,405 | +7,14 % | Ekso Bionics Holdings, Inc.: Bionic P&O Chosen as First Distributor of Ekso Indego Personal Within the Orthotics & Prosthetics Industry | ||
| IMUNON | 0,770 | -1,91 % | Imunon, Inc.: IMUNON Announces IMNN-001 Abstract Accepted for Oral Presentation at 2025 ASCO Annual Meeting | ||
| BEYOND AIR | 0,193 | +4,89 % | Beyond Air: NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to Autism | The FDA designation marks a significant milestone in the development of a novel treatment for a rare neurodevelopmental disorder Plan to initiate first-in-human U.S. clinical trials of lead drug candidate... ► Artikel lesen | |
| AVINGER | 0,340 | -6,08 % | Avinger, Inc.: Avinger Reports Third Quarter 2024 Results | Lower Operating Cost Profile Drives Improved Productivity, Increased Gross Margin REDWOOD CITY, CA / ACCESSWIRE / November 7, 2024 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company... ► Artikel lesen | |
| NOVACYT | 0,473 | +4,53 % | Novacyt legt Termin für Finanzergebnisse 2024 fest | ||
| AROVELLA THERAPEUTICS | 0,049 | +2,08 % | AROVELLA THERAPEUTICS LIMITED: Notification regarding unquoted securities - ALA |
Das Unternehmen MEIHUA INTERNATIONAL MEDICAL TECHNOLOGIES CO LTD kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell -2,66 % bei einem Aktienkurs von 0,282 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MEIHUA INTERNATIONAL MEDICAL TECHNOLOGIES CO LTD finden Sie auf Wallstreet Online.
